Department of Medicine, University of Nevada, Las Vegas-Kirk Kerkorian School of Medicine, Las Vegas NV.
Department of Cardiology and Structural Interventions, West Virginia University Heart and Vascular Institute, Morgantown, WV.
Curr Probl Cardiol. 2023 Jul;48(7):101662. doi: 10.1016/j.cpcardiol.2023.101662. Epub 2023 Mar 1.
Patent foramen ovale (PFO) occluder device has been shown to reduce the chance of recurrent stroke. Per guidelines, stroke is higher in females but procedural efficacy and complications based on sex difference is understudied. The nationwide readmission database (NRD) was used to create sex cohorts using ICD-10 Procedural code for elective PFO occluder device placement performed during the years 2016-2019. The 2 groups were compared using propensity score matching (PSM) and multivariate regression models that matched for confounders to report multivariate odds ratio (mOR) for primary and secondary cardiovascular outcomes. Outcomes included in-hospital mortality, acute kidney injury (AKI), acute ischemic stroke, postprocedure bleeding, and cardiac tamponade. Statistical analysis was performed using STATA v. 17. A total of 5818 patients who underwent PFO occluder device placement were identified, of which 3144 (54.0%) were females, and 2673 (46.0%) were males. There was no difference in periprocedural in-hospital mortality, new onset acute ischemic stroke, postprocedural bleeding, or cardiac tamponade between both sexes undergoing occluder device placement. AKI incidence was higher in males compared to females after matching for CKD (mOR = 0.66; 95% CI [0.48-0.92]; P = 0.016) this can be procedural or can be secondary to volume status or nephrotoxins. Males also had a higher length of stay (LOS) at their index hospitalization (2 days vs 1 day) which led to slightly higher total hospitalization cost ($26,585 vs $24,265). Our data did not show a statistically significant difference in the readmission LOS trends between the 2 groups at 30, 90, and 180 days. This national retrospective cohort study of PFO occluder outcomes shows similar efficacy and complication rates between sexes, with the exception of AKI incidence which was higher in males. AKI occurrence was high in males that can be limited due to unavailability of data about hydration status and nephrotoxic medications.
卵圆孔未闭 (PFO) 封堵器已被证明可降低复发性中风的几率。根据指南,女性中风的风险更高,但基于性别差异的手术效果和并发症研究不足。本研究使用全国再入院数据库 (NRD) ,根据 2016 年至 2019 年期间进行的择期 PFO 封堵器放置的 ICD-10 程序代码,创建了使用性别队列。使用倾向评分匹配 (PSM) 和多变量回归模型对 2 组进行比较,该模型针对混杂因素进行了匹配,以报告主要和次要心血管结局的多变量优势比 (mOR)。纳入的结局包括住院期间死亡率、急性肾损伤 (AKI)、急性缺血性中风、手术后出血和心脏压塞。使用 STATA v. 17 进行统计分析。共确定了 5818 例接受 PFO 封堵器放置的患者,其中 3144 例 (54.0%)为女性,2673 例 (46.0%)为男性。在接受封堵器放置的男女患者中,围手术期住院期间死亡率、新发急性缺血性中风、手术后出血或心脏压塞无差异。在调整 CKD 后,男性 AKI 发生率高于女性 (mOR=0.66;95%CI [0.48-0.92];P=0.016),这可能与手术过程或容量状态或肾毒性药物有关。男性的住院时间 (LOS) 也更长 (2 天比 1 天),导致总住院费用略高 (26585 美元比 24265 美元)。我们的数据显示,两组在 30、90 和 180 天的再入院 LOS 趋势上没有统计学上的显著差异。这项关于 PFO 封堵器结局的全国回顾性队列研究表明,性别之间的疗效和并发症发生率相似,除了 AKI 发生率男性更高。男性 AKI 发生率较高,但由于缺乏有关水化状态和肾毒性药物的数据,这种情况可能会受到限制。